Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers
Status:
Completed
Trial end date:
2021-05-10
Target enrollment:
Participant gender:
Summary
The study proposes to conduct an open-label Phase II trial to evaluate the feasibility,
safety and early efficacy of hydroxychloroquine (HCQ) administration in reduction of
transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and development
of Corona Virus Disease 2019 (COVID-19) in high-risk, healthy acute care provider
participants exposed, directly or indirectly, to COVID-19 patients. There is a more than 50
years track record of safety of HCQ for treatment and prevention of various disease states.
Early data on use of HCQ for COVID treatment suggests anti-viral activity and
immunomodulatory properties for reducing inflammation associated with COVID-19.